Acarbose
Ciprofloxacin may increase the hypoglycemic activities of Acarbose.
Aceclofenac
Aceclofenac may increase the neuroexcitatory activities of Ciprofloxacin.
Acemetacin
Acemetacin may increase the neuroexcitatory activities of Ciprofloxacin.
Advertisement
Acenocoumarol
Ciprofloxacin may increase the anticoagulant activities of Acenocoumarol.
Acetyl salicylate
Acetylsalicylic acid may increase the neuroexcitatory activities of Ciprofloxacin.
Acetyldigitoxin
Acetyldigitoxin may decrease the cardiotoxic activities of Ciprofloxacin.
Advertisement
Adapalene
Adapalene may increase the neuroexcitatory activities of Ciprofloxacin.
Afatinib
The serum concentration of Afatinib can be increased when it is combined with Ciprofloxacin.
Albiglutide
Ciprofloxacin may increase the hypoglycemic activities of Albiglutide.
Advertisement
Albuterol
Salbutamol may increase the QTc-prolonging activities of Ciprofloxacin.
Alclometasone
The risk or severity of adverse effects can be increased when Alclometasone is combined with Ciprofloxacin.
Aldosterone
The risk or severity of adverse effects can be increased when Aldosterone is combined with Ciprofloxacin.
Alfuzosin
Alfuzosin may increase the QTc-prolonging activities of Ciprofloxacin.
Alminoprofen
Alminoprofen may increase the neuroexcitatory activities of Ciprofloxacin.
Alogliptin
Ciprofloxacin may increase the hypoglycemic activities of Alogliptin.
Aloglutamol
Aloglutamol can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Aluminum
Aluminium can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Aluminum Hydroxide
Aluminum hydroxide can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
aluminum hydroxide, dried (USP)
Aluminum hydroxide can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Aluminum Magnesium Silicate
Almasilate can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Amantadine
Amantadine may increase the QTc-prolonging activities of Ciprofloxacin.
AMBROXOL ACEFYLLINATE
The metabolism of Ambroxol acefyllinate can be decreased when combined with Ciprofloxacin.
Ambroxol-Theophylline-7-Acetate
The metabolism of Ambroxol acefyllinate can be decreased when combined with Ciprofloxacin.
Amcinonide
The risk or severity of adverse effects can be increased when Amcinonide is combined with Ciprofloxacin.
Aminophylline
The serum concentration of Aminophylline can be increased when it is combined with Ciprofloxacin.
Amiodarone
Ciprofloxacin may increase the QTc-prolonging activities of Amiodarone.
Amitriptyline
Amitriptyline may increase the QTc-prolonging activities of Ciprofloxacin.
Amoxapine
Amoxapine may increase the QTc-prolonging activities of Ciprofloxacin.
Anagrelide
Ciprofloxacin may increase the QTc-prolonging activities of Anagrelide.
Ancestim
The risk or severity of cytotoxicity can be increased when Ancestim is combined with Ciprofloxacin.
Androstenedione
The risk or severity of adverse effects can be increased when Androstenedione is combined with Ciprofloxacin.
Antipyrine
Antipyrine may increase the neuroexcitatory activities of Ciprofloxacin.
Apalutamide
The serum concentration of Ciprofloxacin can be decreased when it is combined with Apalutamide.
Apazone
Azapropazone may increase the neuroexcitatory activities of Ciprofloxacin.
Apomorphine
Apomorphine may increase the QTc-prolonging activities of Ciprofloxacin.
Apremilast
Apremilast may increase the neuroexcitatory activities of Ciprofloxacin.
Arformoterol
Arformoterol may increase the QTc-prolonging activities of Ciprofloxacin.
Aripiprazole
Aripiprazole may increase the QTc-prolonging activities of Ciprofloxacin.
Arsenic Trioxide
Ciprofloxacin may increase the QTc-prolonging activities of Arsenic trioxide.
Artemether
Ciprofloxacin may increase the QTc-prolonging activities of Artemether.
Asenapine
Ciprofloxacin may increase the QTc-prolonging activities of Asenapine.
Aspirin
Acetylsalicylic acid may increase the neuroexcitatory activities of Ciprofloxacin.
Asunaprevir
The serum concentration of Asunaprevir can be increased when it is combined with Ciprofloxacin.
Atazanavir
Atazanavir may increase the QTc-prolonging activities of Ciprofloxacin.
Atomoxetine
Atomoxetine may increase the QTc-prolonging activities of Ciprofloxacin.
Atorvastatin
The risk or severity of adverse effects can be increased when Ciprofloxacin is combined with Atorvastatin.
Azelastine
Azelastine may increase the neuroexcitatory activities of Ciprofloxacin.
Azilsartan
Azilsartan medoxomil may increase the arrhythmogenic activities of Ciprofloxacin.
Azilsartan kamedoxomil
Azilsartan medoxomil may increase the arrhythmogenic activities of Ciprofloxacin.
Azilsartan Medoxomil
Azilsartan medoxomil may increase the arrhythmogenic activities of Ciprofloxacin.
Azithromycin
Azithromycin may increase the QTc-prolonging activities of Ciprofloxacin.
Balsalazide
Balsalazide may increase the neuroexcitatory activities of Ciprofloxacin.
Beclomethasone Dipropionate
The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Ciprofloxacin.
Bedaquiline
Ciprofloxacin may increase the QTc-prolonging activities of Bedaquiline.
Benazepril
The risk or severity of ventricular arrhythmias can be increased when Benazepril is combined with Ciprofloxacin.
Benzydamine
Benzydamine may increase the neuroexcitatory activities of Ciprofloxacin.
Betamethasone
The risk or severity of adverse effects can be increased when Betamethasone is combined with Ciprofloxacin.
Bevacizumab
Bevacizumab may increase the cardiotoxic activities of Ciprofloxacin.
Bevacizumab-Awwb
Bevacizumab may increase the cardiotoxic activities of Ciprofloxacin.
Bismuth Subcitrate
Bismuth Subcitrate can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Bismuth Subnitrate
Bismuth subnitrate can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Bortezomib
Bortezomib may increase the QTc-prolonging activities of Ciprofloxacin.
Bosutinib
The serum concentration of Bosutinib can be increased when it is combined with Ciprofloxacin.
Bosutinib monohydrate
The serum concentration of Bosutinib can be increased when it is combined with Ciprofloxacin.
Brentuximab Vedotin
The serum concentration of Brentuximab vedotin can be increased when it is combined with Ciprofloxacin.
Bromfenac
Bromfenac may increase the neuroexcitatory activities of Ciprofloxacin.
Bromocriptine
The risk or severity of adverse effects can be increased when Bromocriptine is combined with Ciprofloxacin.
Budesonide
The risk or severity of adverse effects can be increased when Budesonide is combined with Ciprofloxacin.
Bufexamac
Bufexamac may increase the neuroexcitatory activities of Ciprofloxacin.
Buserelin
Buserelin may increase the QTc-prolonging activities of Ciprofloxacin.
Cabazitaxel
The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Ciprofloxacin.
Cabergoline
The risk or severity of adverse effects can be increased when Cabergoline is combined with Ciprofloxacin.
Calcium Acetate
Calcium Acetate can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Calcium Carbonate
Calcium Carbonate can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
CALCIUM CARBONATE, PRECIPITATED
Calcium Carbonate can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Calcium Chloride
Calcium Chloride can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Calcium Chloride Anhydrous
Calcium Chloride can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Calcium Citrate
Calcium Citrate can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Calcium Glubionate
Calcium glubionate can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Calcium gluceptate
Calcium Gluceptate can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Calcium Gluconate
Calcium gluconate can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Calcium Lactate
Calcium lactate can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
CALCIUM LEVULINATE
Calcium levulinate can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Canagliflozin
Ciprofloxacin may increase the hypoglycemic activities of Canagliflozin.
Canagliflozin Anhydrous
Ciprofloxacin may increase the hypoglycemic activities of Canagliflozin.
Candesartan
Candesartan may increase the arrhythmogenic activities of Ciprofloxacin.
Candesartan Cilexetil
Candesartan cilexetil may increase the arrhythmogenic activities of Ciprofloxacin.
Captopril
The risk or severity of ventricular arrhythmias can be increased when Captopril is combined with Ciprofloxacin.
Carbamazepine
The serum concentration of Carbamazepine can be increased when it is combined with Ciprofloxacin.
Carprofen
Carprofen may increase the neuroexcitatory activities of Ciprofloxacin.
Casein Allergenic Extract
Casein can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Celecoxib
Celecoxib may increase the neuroexcitatory activities of Ciprofloxacin.
Ceritinib
Ciprofloxacin may increase the QTc-prolonging activities of Ceritinib.
Cerivastatin
The serum concentration of Cerivastatin can be increased when it is combined with Ciprofloxacin.
Chloroquine
Ciprofloxacin may increase the QTc-prolonging activities of Chloroquine.
Chlorpromazine
Chlorpromazine may increase the QTc-prolonging activities of Ciprofloxacin.
Chlorpropamide
Ciprofloxacin may increase the hypoglycemic activities of Chlorpropamide.
Choline Magnesium Trisalicyclate
Choline magnesium trisalicylate may increase the neuroexcitatory activities of Ciprofloxacin.
Ciclesonide
The risk or severity of adverse effects can be increased when Ciclesonide is combined with Ciprofloxacin.
Cilazapril
The risk or severity of ventricular arrhythmias can be increased when Cilazapril is combined with Ciprofloxacin.
Cisapride
Ciprofloxacin may increase the QTc-prolonging activities of Cisapride.
Citalopram
Ciprofloxacin may increase the QTc-prolonging activities of Citalopram.
Clarithromycin
Ciprofloxacin may increase the QTc-prolonging activities of Clarithromycin.
Clobetasol
The risk or severity of adverse effects can be increased when Clobetasol is combined with Ciprofloxacin.
Clobetasol Propionate
The risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Ciprofloxacin.
Clobetasone
The risk or severity of adverse effects can be increased when Clobetasone is combined with Ciprofloxacin.
Clocortolone
The risk or severity of adverse effects can be increased when Clocortolone is combined with Ciprofloxacin.
Clomipramine
Clomipramine may increase the QTc-prolonging activities of Ciprofloxacin.
Clonixin
Clonixin may increase the neuroexcitatory activities of Ciprofloxacin.
Clozapine
Ciprofloxacin may increase the QTc-prolonging activities of Clozapine.
Colchicine
The serum concentration of Colchicine can be increased when it is combined with Ciprofloxacin.
Cortisone Acetate
The risk or severity of adverse effects can be increased when Cortisone acetate is combined with Ciprofloxacin.
Crizotinib
Ciprofloxacin may increase the QTc-prolonging activities of Crizotinib.
Curcumin
Curcumin may increase the neuroexcitatory activities of Ciprofloxacin.
Cyclophosphamide
Cyclophosphamide may increase the cardiotoxic activities of Ciprofloxacin.
Cyclophosphamide Anhydrous
Cyclophosphamide may increase the cardiotoxic activities of Ciprofloxacin.
Dabigatran Etexilate
The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Ciprofloxacin.
Dabrafenib
Dabrafenib may increase the QTc-prolonging activities of Ciprofloxacin.
Dapagliflozin
Ciprofloxacin may increase the hypoglycemic activities of Dapagliflozin.
Dasatinib
Dasatinib may increase the QTc-prolonging activities of Ciprofloxacin.
Dasatinib Anhydrous
Dasatinib may increase the QTc-prolonging activities of Ciprofloxacin.
Deflazacort
The risk or severity of adverse effects can be increased when Deflazacort is combined with Ciprofloxacin.
Degarelix
Degarelix may increase the QTc-prolonging activities of Ciprofloxacin.
Desflurane
Desflurane may increase the QTc-prolonging activities of Ciprofloxacin.
Desipramine
Desipramine may increase the QTc-prolonging activities of Ciprofloxacin.
Deslanoside
Deslanoside may decrease the cardiotoxic activities of Ciprofloxacin.
Desonide
The risk or severity of adverse effects can be increased when Desonide is combined with Ciprofloxacin.
Desoximetasone
The risk or severity of adverse effects can be increased when Desoximetasone is combined with Ciprofloxacin.
Desoxycorticosterone acetate
The risk or severity of adverse effects can be increased when Desoxycorticosterone acetate is combined with Ciprofloxacin.
Desoxycorticosterone Pivalate
The risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Ciprofloxacin.
Deutetrabenazine
Ciprofloxacin may increase the QTc-prolonging activities of Deutetrabenazine.
Dexamethasone
The risk or severity of adverse effects can be increased when Dexamethasone is combined with Ciprofloxacin.
Diclofenac
Diclofenac may increase the neuroexcitatory activities of Ciprofloxacin.
Dicumarol
Ciprofloxacin may increase the anticoagulant activities of Dicoumarol.
Didanosine
The serum concentration of Didanosine can be decreased when it is combined with Ciprofloxacin.
Diflorasone
The risk or severity of adverse effects can be increased when Diflorasone is combined with Ciprofloxacin.
Diflucortolone
The risk or severity of adverse effects can be increased when Difluocortolone is combined with Ciprofloxacin.
Diflunisal
Diflunisal may increase the neuroexcitatory activities of Ciprofloxacin.
Difluprednate
The risk or severity of adverse effects can be increased when Difluprednate is combined with Ciprofloxacin.
Digitoxin
Digitoxin may decrease the cardiotoxic activities of Ciprofloxacin.
Digoxin
Digoxin may decrease the cardiotoxic activities of Ciprofloxacin.
Dihydroergocornine
The risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Ciprofloxacin.
Dihydroergocristine
The risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Ciprofloxacin.
Dihydroergotamine
The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Ciprofloxacin.
Dimenhydrinate
The serum concentration of Dimenhydrinate can be increased when it is combined with Ciprofloxacin.
Diphenhydramine
Diphenhydramine may increase the QTc-prolonging activities of Ciprofloxacin.
Dipyrone
Metamizole may increase the neuroexcitatory activities of Ciprofloxacin.
Disopyramide
Ciprofloxacin may increase the QTc-prolonging activities of Disopyramide.
Docetaxel
The risk or severity of adverse effects can be increased when Docetaxel is combined with Ciprofloxacin.
DOCETAXEL ANHYDROUS
The risk or severity of adverse effects can be increased when Docetaxel is combined with Ciprofloxacin.
Dofetilide
Ciprofloxacin may increase the QTc-prolonging activities of Dofetilide.
Dolasetron
Ciprofloxacin may increase the QTc-prolonging activities of Dolasetron.
Domperidone
Ciprofloxacin may increase the QTc-prolonging activities of Domperidone.
Doxepin
Doxepin may increase the QTc-prolonging activities of Ciprofloxacin.
Doxorubicin
The serum concentration of Doxorubicin can be increased when it is combined with Ciprofloxacin.
Doxorubicin Hydrochloride
The serum concentration of Doxorubicin can be increased when it is combined with Ciprofloxacin.
Dronedarone
Ciprofloxacin may increase the QTc-prolonging activities of Dronedarone.
Droperidol
Droperidol may increase the QTc-prolonging activities of Ciprofloxacin.
Droxicam
Droxicam may increase the neuroexcitatory activities of Ciprofloxacin.
Dulaglutide
Ciprofloxacin may increase the hypoglycemic activities of Dulaglutide.
Dyphylline
The serum concentration of Dyphylline can be increased when it is combined with Ciprofloxacin.
Edoxaban
The serum concentration of Edoxaban can be increased when it is combined with Ciprofloxacin.
Eliglustat
Ciprofloxacin may increase the QTc-prolonging activities of Eliglustat.
Empagliflozin
Ciprofloxacin may increase the hypoglycemic activities of Empagliflozin.
Enalapril
The risk or severity of ventricular arrhythmias can be increased when Enalapril is combined with Ciprofloxacin.
Enalaprilat
The risk or severity of ventricular arrhythmias can be increased when Enalaprilat is combined with Ciprofloxacin.
Enalaprilat Anhydrous
The risk or severity of ventricular arrhythmias can be increased when Enalaprilat is combined with Ciprofloxacin.
Eprosartan
Eprosartan may increase the arrhythmogenic activities of Ciprofloxacin.
Ergonovine
The risk or severity of adverse effects can be increased when Ergonovine is combined with Ciprofloxacin.
Ergotamine
The risk or severity of adverse effects can be increased when Ergotamine is combined with Ciprofloxacin.
Eribulin
Eribulin may increase the QTc-prolonging activities of Ciprofloxacin.
Erlotinib
The serum concentration of Erlotinib can be increased when it is combined with Ciprofloxacin.
Erythromycin
Erythromycin may increase the QTc-prolonging activities of Ciprofloxacin.
Escitalopram
Ciprofloxacin may increase the QTc-prolonging activities of Escitalopram.
Estrone
The risk or severity of adverse effects can be increased when Estrone is combined with Ciprofloxacin.
Etanercept
Etanercept may increase the neuroexcitatory activities of Ciprofloxacin.
Etodolac
Etodolac may increase the neuroexcitatory activities of Ciprofloxacin.
Etofenamate
Etofenamate may increase the neuroexcitatory activities of Ciprofloxacin.
Etoricoxib
Etoricoxib may increase the neuroexcitatory activities of Ciprofloxacin.
Evening primrose oil
Evening primrose oil may increase the neuroexcitatory activities of Ciprofloxacin.
Everolimus
The serum concentration of Everolimus can be increased when it is combined with Ciprofloxacin.
Exenatide
Ciprofloxacin may increase the hypoglycemic activities of Exenatide.
Ezogabine
Ezogabine may increase the QTc-prolonging activities of Ciprofloxacin.
Famotidine
Famotidine may increase the QTc-prolonging activities of Ciprofloxacin.
Felbamate
Felbamate may increase the QTc-prolonging activities of Ciprofloxacin.
Felbinac
Felbinac may increase the neuroexcitatory activities of Ciprofloxacin.
Fenbufen
Fenbufen may increase the neuroexcitatory activities of Ciprofloxacin.
Fenoprofen
Fenoprofen may increase the neuroexcitatory activities of Ciprofloxacin.
Ferric Carboxymaltose
The serum concentration of Ciprofloxacin can be decreased when it is combined with Ferric Carboxymaltose.
Ferric Pyrophosphate
The serum concentration of Ciprofloxacin can be decreased when it is combined with Ferric pyrophosphate.
Ferulic Acid
Ferulic acid may increase the neuroexcitatory activities of Ciprofloxacin.
Fingolimod
Fingolimod may increase the QTc-prolonging activities of Ciprofloxacin.
Flecainide
Ciprofloxacin may increase the QTc-prolonging activities of Flecainide.
Floctafenine
Floctafenine may increase the neuroexcitatory activities of Ciprofloxacin.
Fluconazole
Fluconazole may increase the QTc-prolonging activities of Ciprofloxacin.
Fludrocortisone
The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Ciprofloxacin.
Fluindione
Ciprofloxacin may increase the anticoagulant activities of Fluindione.
Flumethasone
The risk or severity of adverse effects can be increased when Flumethasone is combined with Ciprofloxacin.
Flunisolide
The risk or severity of adverse effects can be increased when Flunisolide is combined with Ciprofloxacin.
Flunisolide Anhydrous (obsolete)
The risk or severity of adverse effects can be increased when Flunisolide is combined with Ciprofloxacin.
Fluocinolone Acetonide
The risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Ciprofloxacin.
Fluocinonide
The risk or severity of adverse effects can be increased when Fluocinonide is combined with Ciprofloxacin.
Fluocortolone
The risk or severity of adverse effects can be increased when Fluocortolone is combined with Ciprofloxacin.
Fluorometholone
The risk or severity of adverse effects can be increased when Fluorometholone is combined with Ciprofloxacin.
Fluoxetine
Ciprofloxacin may increase the QTc-prolonging activities of Fluoxetine.
Flupenthixol
Ciprofloxacin may increase the QTc-prolonging activities of Flupentixol.
FLUPREDNIDENE
The risk or severity of adverse effects can be increased when Fluprednidene is combined with Ciprofloxacin.
Fluprednisolone
The risk or severity of adverse effects can be increased when Fluprednisolone is combined with Ciprofloxacin.
Flurandrenolide
The risk or severity of adverse effects can be increased when Flurandrenolide is combined with Ciprofloxacin.
Flurbiprofen
Flurbiprofen may increase the neuroexcitatory activities of Ciprofloxacin.
Fluticasone
The risk or severity of adverse effects can be increased when Fluticasone is combined with Ciprofloxacin.
Fluticasone Furoate
The risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Ciprofloxacin.
Fluticasone propionate
The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Ciprofloxacin.
Fluvastatin
The serum concentration of Fluvastatin can be increased when it is combined with Ciprofloxacin.
Formestane
The risk or severity of adverse effects can be increased when Formestane is combined with Ciprofloxacin.
Formoterol
Formoterol may increase the QTc-prolonging activities of Ciprofloxacin.
Foscarnet
Foscarnet may increase the QTc-prolonging activities of Ciprofloxacin.
Fosinopril
The risk or severity of ventricular arrhythmias can be increased when Fosinopril is combined with Ciprofloxacin.
Fosphenytoin
Fosphenytoin may increase the QTc-prolonging activities of Ciprofloxacin.
Gadobenate
Ciprofloxacin may increase the QTc-prolonging activities of Gadobenic acid.
Galantamine
Galantamine may increase the QTc-prolonging activities of Ciprofloxacin.
Gemifloxacin
Ciprofloxacin may increase the QTc-prolonging activities of Gemifloxacin.
Gemifloxacin Mesylate
Ciprofloxacin may increase the QTc-prolonging activities of Gemifloxacin.
Gliclazide
Ciprofloxacin may increase the hypoglycemic activities of Gliclazide.
Glimepiride
Ciprofloxacin may increase the hypoglycemic activities of Glimepiride.
Glipizide
Ciprofloxacin may increase the hypoglycemic activities of Glipizide.
Glyburide
Ciprofloxacin may increase the hypoglycemic activities of Glyburide.
Goserelin
Goserelin may increase the QTc-prolonging activities of Ciprofloxacin.
Granisetron
Ciprofloxacin may increase the QTc-prolonging activities of Granisetron.
Halcinonide
The risk or severity of adverse effects can be increased when Halcinonide is combined with Ciprofloxacin.
Halobetasol
The risk or severity of adverse effects can be increased when Ulobetasol is combined with Ciprofloxacin.
Haloperidol
Haloperidol may increase the QTc-prolonging activities of Ciprofloxacin.
Histrelin
Histrelin may increase the QTc-prolonging activities of Ciprofloxacin.
Hydrocortisone
The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Ciprofloxacin.
Hydrotalcite
Hydrotalcite can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Hydroxyzine
Hydroxyzine may increase the QTc-prolonging activities of Ciprofloxacin.
Ibandronate
Ibandronate may increase the QTc-prolonging activities of Ciprofloxacin.
Ibandronic Acid
Ibandronate may increase the QTc-prolonging activities of Ciprofloxacin.
Ibrutinib
The serum concentration of Ibrutinib can be increased when it is combined with Ciprofloxacin.
Ibuprofen
Ibuprofen may increase the neuroexcitatory activities of Ciprofloxacin.
Ibutilide
Ciprofloxacin may increase the QTc-prolonging activities of Ibutilide.
Icatibant
Icatibant may increase the neuroexcitatory activities of Ciprofloxacin.
Iloperidone
Ciprofloxacin may increase the QTc-prolonging activities of Iloperidone.
Imidapril
The risk or severity of ventricular arrhythmias can be increased when Imidapril is combined with Ciprofloxacin.
Imipramine
Imipramine may increase the QTc-prolonging activities of Ciprofloxacin.
Indacaterol
Indacaterol may increase the QTc-prolonging activities of Ciprofloxacin.
Indapamide
Indapamide may increase the QTc-prolonging activities of Ciprofloxacin.
Indobufen
Indobufen may increase the neuroexcitatory activities of Ciprofloxacin.
Indomethacin
Indomethacin may increase the neuroexcitatory activities of Ciprofloxacin.
Insulin Detemir
Ciprofloxacin may increase the hypoglycemic activities of Insulin Detemir.
Insulin Glargine
Ciprofloxacin may increase the hypoglycemic activities of Insulin Glargine.
insulin human, rDNA origin
Ciprofloxacin may increase the hypoglycemic activities of Insulin Human.
Insulin Lispro
Ciprofloxacin may increase the hypoglycemic activities of Insulin Lispro.
Insulin, Aspart Protamine, Human
Ciprofloxacin may increase the hypoglycemic activities of Insulin Aspart.
Insulin, Aspart, Human
Ciprofloxacin may increase the hypoglycemic activities of Insulin Aspart.
Insulin, Glulisine, Human
Ciprofloxacin may increase the hypoglycemic activities of Insulin Glulisine.
Insulin, Protamine Lispro, Human
Ciprofloxacin may increase the hypoglycemic activities of Insulin Lispro.
Irbesartan
Irbesartan may increase the arrhythmogenic activities of Ciprofloxacin.
Iron
The serum concentration of Ciprofloxacin can be decreased when it is combined with Iron.
Iron Carbonyl
The serum concentration of Ciprofloxacin can be decreased when it is combined with Iron.
Iron Sucrose
The serum concentration of Ciprofloxacin can be decreased when it is combined with Iron saccharate.
Iron-Dextran Complex
The serum concentration of Ciprofloxacin can be decreased when it is combined with Iron Dextran.
Isavuconazole
The serum concentration of Ciprofloxacin can be increased when it is combined with Isavuconazole.
Isoflurane
Isoflurane may increase the QTc-prolonging activities of Ciprofloxacin.
Isradipine
Isradipine may increase the QTc-prolonging activities of Ciprofloxacin.
Itraconazole
Itraconazole may increase the QTc-prolonging activities of Ciprofloxacin.
Ivabradine
Ivabradine may increase the QTc-prolonging activities of Ciprofloxacin.
Kebuzone
Kebuzone may increase the neuroexcitatory activities of Ciprofloxacin.
Ketoconazole
Ketoconazole may increase the QTc-prolonging activities of Ciprofloxacin.
Ketoprofen
Ketoprofen may increase the neuroexcitatory activities of Ciprofloxacin.
Ketorolac
Ketorolac may increase the neuroexcitatory activities of Ciprofloxacin.
Lanthanum Carbonate
The serum concentration of Ciprofloxacin can be decreased when it is combined with Lanthanum carbonate.
Lapatinib
Lapatinib may increase the QTc-prolonging activities of Ciprofloxacin.
Ledipasvir
The serum concentration of Ledipasvir can be increased when it is combined with Ciprofloxacin.
Leflunomide
Leflunomide may increase the neuroexcitatory activities of Ciprofloxacin.
Lenvatinib
Ciprofloxacin may increase the QTc-prolonging activities of Lenvatinib.
Lenvatinib Mesylate
Ciprofloxacin may increase the QTc-prolonging activities of Lenvatinib.
Leuprolide
Leuprolide may increase the QTc-prolonging activities of Ciprofloxacin.
Levofloxacin
Ciprofloxacin may increase the QTc-prolonging activities of Levofloxacin.
Levofloxacin Anhydrous
Ciprofloxacin may increase the QTc-prolonging activities of Levofloxacin.
Levothyroxine
The serum concentration of Levothyroxine can be decreased when it is combined with Ciprofloxacin.
Limonene, (+)-
(4R)-limonene may increase the neuroexcitatory activities of Ciprofloxacin.
Liothyronine
The serum concentration of Liothyronine can be decreased when it is combined with Ciprofloxacin.
Liraglutide
Ciprofloxacin may increase the hypoglycemic activities of Liraglutide.
Lisinopril
The risk or severity of ventricular arrhythmias can be increased when Lisinopril is combined with Ciprofloxacin.
Lisinopril Anhydrous
The risk or severity of ventricular arrhythmias can be increased when Lisinopril is combined with Ciprofloxacin.
Lisuride
The risk or severity of adverse effects can be increased when Lisuride is combined with Ciprofloxacin.
Lithium
Lithium may increase the QTc-prolonging activities of Ciprofloxacin.
Lithium Cation
Lithium may increase the QTc-prolonging activities of Ciprofloxacin.
Lopinavir
Ciprofloxacin may increase the QTc-prolonging activities of Lopinavir.
Lornoxicam
Lornoxicam may increase the neuroexcitatory activities of Ciprofloxacin.
Losartan
Losartan may increase the arrhythmogenic activities of Ciprofloxacin.
Loteprednol
The risk or severity of adverse effects can be increased when Loteprednol is combined with Ciprofloxacin.
Lovastatin
The serum concentration of Lovastatin can be increased when it is combined with Ciprofloxacin.
Loxoprofen
Loxoprofen may increase the neuroexcitatory activities of Ciprofloxacin.
Lumacaftor
The serum concentration of Ciprofloxacin can be decreased when it is combined with Lumacaftor.
Lumefantrine
Ciprofloxacin may increase the QTc-prolonging activities of Lumefantrine.
Macimorelin
Ciprofloxacin may increase the QTc-prolonging activities of Macimorelin.
Magaldrate
Magaldrate can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Magnesium Carbonate
Magnesium carbonate can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Magnesium Hydroxide
Magnesium hydroxide can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Magnesium Oxide
Magnesium oxide can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Magnesium Salicylate
The serum concentration of Ciprofloxacin can be decreased when it is combined with Magnesium salicylate.
Magnesium silicate
Magnesium silicate can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Magnesium Sulfate
The serum concentration of Ciprofloxacin can be decreased when it is combined with Magnesium sulfate.
MAGNESIUM SULFATE ANHYDROUS
The serum concentration of Ciprofloxacin can be decreased when it is combined with Magnesium sulfate.
Magnesium Trisilicate
Magnesium Trisilicate can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Maprotiline
Maprotiline may increase the QTc-prolonging activities of Ciprofloxacin.
Masoprocol
Masoprocol may increase the neuroexcitatory activities of Ciprofloxacin.
Mecasermin
Ciprofloxacin may increase the hypoglycemic activities of Mecasermin.
Mecasermin Rinfabate
Ciprofloxacin may increase the hypoglycemic activities of Mecasermin.
Meclofenamate
Meclofenamic acid may increase the neuroexcitatory activities of Ciprofloxacin.
Meclofenamic Acid
Meclofenamic acid may increase the neuroexcitatory activities of Ciprofloxacin.
Medrysone
The risk or severity of adverse effects can be increased when Medrysone is combined with Ciprofloxacin.
Mefenamic Acid
Mefenamic acid may increase the neuroexcitatory activities of Ciprofloxacin.
Mefloquine
Mefloquine may increase the QTc-prolonging activities of Ciprofloxacin.
Meloxicam
Meloxicam may increase the neuroexcitatory activities of Ciprofloxacin.
Mesalamine
Mesalazine may increase the neuroexcitatory activities of Ciprofloxacin.
Metergoline
The risk or severity of adverse effects can be increased when Metergoline is combined with Ciprofloxacin.
Metformin
Ciprofloxacin may increase the hypoglycemic activities of Metformin.
Methadone
Methadone may increase the QTc-prolonging activities of Ciprofloxacin.
Methotrexate
The serum concentration of Methotrexate can be increased when it is combined with Ciprofloxacin.
Methotrimeprazine
Methotrimeprazine may increase the QTc-prolonging activities of Ciprofloxacin.
Methylergonovine
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Ciprofloxacin.
Methylprednisolone
The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Ciprofloxacin.
Methysergide
The risk or severity of adverse effects can be increased when Methysergide is combined with Ciprofloxacin.
Metoclopramide
Metoclopramide may increase the QTc-prolonging activities of Ciprofloxacin.
Metronidazole
Metronidazole may increase the QTc-prolonging activities of Ciprofloxacin.
Mifepristone
Ciprofloxacin may increase the QTc-prolonging activities of Mifepristone.
Miglitol
Ciprofloxacin may increase the hypoglycemic activities of Miglitol.
Mirabegron
Mirabegron may increase the QTc-prolonging activities of Ciprofloxacin.
Mirtazapine
Mirtazapine may increase the QTc-prolonging activities of Ciprofloxacin.
Moexipril
The risk or severity of ventricular arrhythmias can be increased when Moexipril is combined with Ciprofloxacin.
Mometasone
The risk or severity of adverse effects can be increased when Mometasone is combined with Ciprofloxacin.
Moxifloxacin
Moxifloxacin may increase the QTc-prolonging activities of Ciprofloxacin.
MYCOPHENOLATE
The serum concentration of Mycophenolic acid can be decreased when it is combined with Ciprofloxacin.
Mycophenolate Mofetil
Mycophenolate mofetil may increase the neuroexcitatory activities of Ciprofloxacin.
Mycophenolic Acid
The serum concentration of Mycophenolic acid can be decreased when it is combined with Ciprofloxacin.
Nabumetone
Nabumetone may increase the neuroexcitatory activities of Ciprofloxacin.
Naftifine
Naftifine may increase the neuroexcitatory activities of Ciprofloxacin.
Naloxegol
The serum concentration of Naloxegol can be increased when it is combined with Ciprofloxacin.
Naproxen
Naproxen may increase the neuroexcitatory activities of Ciprofloxacin.
Nateglinide
Ciprofloxacin may increase the hypoglycemic activities of Nateglinide.
Nelfinavir
Nelfinavir may increase the QTc-prolonging activities of Ciprofloxacin.
Nepafenac
Nepafenac may increase the neuroexcitatory activities of Ciprofloxacin.
Nicardipine
Nicardipine may increase the QTc-prolonging activities of Ciprofloxacin.
Nicergoline
The risk or severity of adverse effects can be increased when Nicergoline is combined with Ciprofloxacin.
Niflumic Acid
Niflumic Acid may increase the neuroexcitatory activities of Ciprofloxacin.
Nilotinib
Ciprofloxacin may increase the QTc-prolonging activities of Nilotinib.
Nimesulide
Nimesulide may increase the neuroexcitatory activities of Ciprofloxacin.
Nintedanib
The serum concentration of Nintedanib can be increased when it is combined with Ciprofloxacin.
Norfloxacin
Norfloxacin may increase the QTc-prolonging activities of Ciprofloxacin.
Nortriptyline
Nortriptyline may increase the QTc-prolonging activities of Ciprofloxacin.
Octreotide
Octreotide may increase the QTc-prolonging activities of Ciprofloxacin.
Oenothera biennis seed extract
Evening primrose oil may increase the neuroexcitatory activities of Ciprofloxacin.
Ofloxacin
Ciprofloxacin may increase the QTc-prolonging activities of Ofloxacin.
Olanzapine
Olanzapine may increase the QTc-prolonging activities of Ciprofloxacin.
Olmesartan
Olmesartan may increase the arrhythmogenic activities of Ciprofloxacin.
Olodaterol
Olodaterol may increase the QTc-prolonging activities of Ciprofloxacin.
Olopatadine
Olopatadine may increase the neuroexcitatory activities of Ciprofloxacin.
Olsalazine
Olsalazine may increase the neuroexcitatory activities of Ciprofloxacin.
Ondansetron
Ciprofloxacin may increase the QTc-prolonging activities of Ondansetron.
Ouabain
Ouabain may decrease the cardiotoxic activities of Ciprofloxacin.
Ovine Digoxin Immune Fab
Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Ciprofloxacin.
Oxaprozin
Oxaprozin may increase the neuroexcitatory activities of Ciprofloxacin.
Oxyphenbutazone
Oxyphenbutazone may increase the neuroexcitatory activities of Ciprofloxacin.
Oxytocin
Oxytocin may increase the QTc-prolonging activities of Ciprofloxacin.
Paclitaxel
The risk or severity of adverse effects can be increased when Paclitaxel is combined with Ciprofloxacin.
Paliperidone
Ciprofloxacin may increase the QTc-prolonging activities of Paliperidone.
Palmidrol
Palmidrol may increase the neuroexcitatory activities of Ciprofloxacin.
Panobinostat
Ciprofloxacin may increase the QTc-prolonging activities of Panobinostat.
Paramethasone
The risk or severity of adverse effects can be increased when Paramethasone is combined with Ciprofloxacin.
Parecoxib
Parecoxib may increase the neuroexcitatory activities of Ciprofloxacin.
Paroxetine
Paroxetine may increase the QTc-prolonging activities of Ciprofloxacin.
Parthenolide
Parthenolide may increase the neuroexcitatory activities of Ciprofloxacin.
Pasireotide
Pasireotide may increase the QTc-prolonging activities of Ciprofloxacin.
Pazopanib
The serum concentration of Pazopanib can be increased when it is combined with Ciprofloxacin.
Pentamidine
Ciprofloxacin may increase the QTc-prolonging activities of Pentamidine.
Perflutren
Ciprofloxacin may increase the QTc-prolonging activities of Perflutren.
Pergolide
The risk or severity of adverse effects can be increased when Pergolide is combined with Ciprofloxacin.
Perindopril
The risk or severity of ventricular arrhythmias can be increased when Perindopril is combined with Ciprofloxacin.
Phenindione
Ciprofloxacin may increase the anticoagulant activities of Phenindione.
Phenprocoumon
Ciprofloxacin may increase the anticoagulant activities of Phenprocoumon.
Phenylbutazone
Phenylbutazone may increase the neuroexcitatory activities of Ciprofloxacin.
Phenytoin
The therapeutic efficacy of Phenytoin can be decreased when used in combination with Ciprofloxacin.
Picosulfuric Acid
The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Ciprofloxacin.
Pimecrolimus
Pimecrolimus may increase the neuroexcitatory activities of Ciprofloxacin.
Pimozide
Ciprofloxacin may increase the QTc-prolonging activities of Pimozide.
Pioglitazone
Ciprofloxacin may increase the hypoglycemic activities of Pioglitazone.
Pirfenidone
The serum concentration of Pirfenidone can be increased when it is combined with Ciprofloxacin.
Piroxicam
Piroxicam may increase the neuroexcitatory activities of Ciprofloxacin.
Piroxicam-Beta-Cyclodextrin
Piroxicam may increase the neuroexcitatory activities of Ciprofloxacin.
Pitavastatin
The serum concentration of Pitavastatin can be increased when it is combined with Ciprofloxacin.
Posaconazole
Posaconazole may increase the QTc-prolonging activities of Ciprofloxacin.
Pramlintide
Ciprofloxacin may increase the hypoglycemic activities of Pramlintide.
Prasterone
The risk or severity of adverse effects can be increased when Prasterone is combined with Ciprofloxacin.
Pravastatin
The serum concentration of Pravastatin can be increased when it is combined with Ciprofloxacin.
Prednicarbate
The risk or severity of adverse effects can be increased when Prednicarbate is combined with Ciprofloxacin.
Prednisolone
The risk or severity of adverse effects can be increased when Prednisolone is combined with Ciprofloxacin.
Prednisone
The risk or severity of adverse effects can be increased when Prednisone is combined with Ciprofloxacin.
Pregnenolone
The risk or severity of adverse effects can be increased when Pregnenolone is combined with Ciprofloxacin.
Primaquine
Ciprofloxacin may increase the QTc-prolonging activities of Primaquine.
Probenecid
The serum concentration of Ciprofloxacin can be increased when it is combined with Probenecid.
Procainamide
Ciprofloxacin may increase the QTc-prolonging activities of Procainamide.
Promazine
Promazine may increase the QTc-prolonging activities of Ciprofloxacin.
Promethazine
Promethazine may increase the QTc-prolonging activities of Ciprofloxacin.
Propafenone
Ciprofloxacin may increase the QTc-prolonging activities of Propafenone.
Propofol
Propofol may increase the QTc-prolonging activities of Ciprofloxacin.
Proscillaridin
Proscillaridin may decrease the cardiotoxic activities of Ciprofloxacin.
Protriptyline
Protriptyline may increase the QTc-prolonging activities of Ciprofloxacin.
Quetiapine
Ciprofloxacin may increase the QTc-prolonging activities of Quetiapine.
Quetiapine fumarate
Ciprofloxacin may increase the QTc-prolonging activities of Quetiapine.
Quinapril
Quinapril can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Quinidine
Ciprofloxacin may increase the QTc-prolonging activities of Quinidine.
Quinine
Ciprofloxacin may increase the QTc-prolonging activities of Quinine.
Ramipril
The risk or severity of ventricular arrhythmias can be increased when Ramipril is combined with Ciprofloxacin.
Ranolazine
The serum concentration of Ranolazine can be increased when it is combined with Ciprofloxacin.
Regular Insulin, Human
Ciprofloxacin may increase the hypoglycemic activities of Insulin Human.
Repaglinide
Ciprofloxacin may increase the hypoglycemic activities of Repaglinide.
Rescinnamine
The risk or severity of ventricular arrhythmias can be increased when Rescinnamine is combined with Ciprofloxacin.
Resveratrol
Resveratrol may increase the neuroexcitatory activities of Ciprofloxacin.
Ribociclib
The risk or severity of QTc prolongation can be increased when Ribociclib is combined with Ciprofloxacin.
Rifaximin
The serum concentration of Rifaximin can be increased when it is combined with Ciprofloxacin.
Rilpivirine
The serum concentration of Rilpivirine can be increased when it is combined with Ciprofloxacin.
Rimexolone
The risk or severity of adverse effects can be increased when Rimexolone is combined with Ciprofloxacin.
Risperidone
Risperidone may increase the QTc-prolonging activities of Ciprofloxacin.
Ritonavir
Ritonavir may increase the QTc-prolonging activities of Ciprofloxacin.
Rofecoxib
Rofecoxib may increase the neuroexcitatory activities of Ciprofloxacin.
Roflumilast
The serum concentration of Roflumilast can be increased when it is combined with Ciprofloxacin.
Ropinirole
The serum concentration of Ropinirole can be increased when it is combined with Ciprofloxacin.
Ropivacaine
The serum concentration of Ropivacaine can be increased when it is combined with Ciprofloxacin.
Rosiglitazone
Ciprofloxacin may increase the hypoglycemic activities of Rosiglitazone.
Rosuvastatin
The serum concentration of Rosuvastatin can be increased when it is combined with Ciprofloxacin.
Sacubitril
Sacubitril may increase the arrhythmogenic activities of Ciprofloxacin.
Salicylamide
Salicylamide may increase the neuroexcitatory activities of Ciprofloxacin.
Salicylic Acid
Salicylic acid may increase the neuroexcitatory activities of Ciprofloxacin.
Salmeterol
Salmeterol may increase the QTc-prolonging activities of Ciprofloxacin.
Salsalate
Salsalate may increase the neuroexcitatory activities of Ciprofloxacin.
Saquinavir
Ciprofloxacin may increase the QTc-prolonging activities of Saquinavir.
Saquinavir Mesylate
Ciprofloxacin may increase the QTc-prolonging activities of Saquinavir.
Saralasin
Saralasin may increase the arrhythmogenic activities of Ciprofloxacin.
Saxagliptin
Ciprofloxacin may increase the hypoglycemic activities of Saxagliptin.
Saxagliptin Anhydrous
Ciprofloxacin may increase the hypoglycemic activities of Saxagliptin.
Serratiopeptidase
Serrapeptase may increase the neuroexcitatory activities of Ciprofloxacin.
Sertraline
Sertraline may increase the QTc-prolonging activities of Ciprofloxacin.
Sevelamer
Sevelamer can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Sevoflurane
Sevoflurane may increase the QTc-prolonging activities of Ciprofloxacin.
Silodosin
The serum concentration of Silodosin can be increased when it is combined with Ciprofloxacin.
Simvastatin
The serum concentration of Simvastatin can be increased when it is combined with Ciprofloxacin.
Sitagliptin
Ciprofloxacin may increase the hypoglycemic activities of Sitagliptin.
Sitagliptin Phosphate
Ciprofloxacin may increase the hypoglycemic activities of Sitagliptin.
Sodium Bicarbonate
Sodium bicarbonate can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Solifenacin
Solifenacin may increase the QTc-prolonging activities of Ciprofloxacin.
Sorafenib
Sorafenib may increase the QTc-prolonging activities of Ciprofloxacin.
Sotalol
Ciprofloxacin may increase the QTc-prolonging activities of Sotalol.
Spirapril
The risk or severity of ventricular arrhythmias can be increased when Spirapril is combined with Ciprofloxacin.
Spironolactone
Spironolactone may increase the arrhythmogenic activities of Ciprofloxacin.
Sucralfate
The serum concentration of Ciprofloxacin can be decreased when it is combined with Sucralfate.
Sucroferric Oxyhydroxide
The serum concentration of Ciprofloxacin can be decreased when it is combined with Iron saccharate.
Sulfadiazine
Ciprofloxacin may increase the hypoglycemic activities of Sulfadiazine.
Sulfamethoxazole
Sulfamethoxazole may increase the QTc-prolonging activities of Ciprofloxacin.
Sulfasalazine
Sulfasalazine may increase the neuroexcitatory activities of Ciprofloxacin.
Sulfisoxazole
Sulfisoxazole may increase the QTc-prolonging activities of Ciprofloxacin.
Sulindac
Sulindac may increase the neuroexcitatory activities of Ciprofloxacin.
Sunitinib
Sunitinib may increase the QTc-prolonging activities of Ciprofloxacin.
Suprofen
Suprofen may increase the neuroexcitatory activities of Ciprofloxacin.
Tamoxifen
Tamoxifen may increase the QTc-prolonging activities of Ciprofloxacin.
Telavancin
Ciprofloxacin may increase the QTc-prolonging activities of Telavancin.
Telithromycin
Ciprofloxacin may increase the QTc-prolonging activities of Telithromycin.
Telmisartan
Telmisartan may increase the arrhythmogenic activities of Ciprofloxacin.
Tenoxicam
Tenoxicam may increase the neuroexcitatory activities of Ciprofloxacin.
Terbutaline
Terbutaline may increase the QTc-prolonging activities of Ciprofloxacin.
Terbutaline Sulfate
Terbutaline may increase the QTc-prolonging activities of Ciprofloxacin.
Teriflunomide
Teriflunomide may increase the neuroexcitatory activities of Ciprofloxacin.
Tetrabenazine
Ciprofloxacin may increase the QTc-prolonging activities of Tetrabenazine.
Theophylline
The serum concentration of Theophylline can be increased when it is combined with Ciprofloxacin.
Theophylline anhydrous
The serum concentration of Theophylline can be increased when it is combined with Ciprofloxacin.
Thioridazine
Ciprofloxacin may increase the QTc-prolonging activities of Thioridazine.
Thiothixene
Thiothixene may increase the QTc-prolonging activities of Ciprofloxacin.
Thyroid, Porcine
The serum concentration of Thyroid, porcine can be decreased when it is combined with Ciprofloxacin.
Tiaprofenic Acid
Tiaprofenic acid may increase the neuroexcitatory activities of Ciprofloxacin.
Tixocortol
The risk or severity of adverse effects can be increased when Tixocortol is combined with Ciprofloxacin.
Tizanidine
Tizanidine may increase the QTc-prolonging activities of Ciprofloxacin.
Tolazamide
Ciprofloxacin may increase the hypoglycemic activities of Tolazamide.
Tolbutamide
Ciprofloxacin may increase the hypoglycemic activities of Tolbutamide.
Tolfenamic Acid
Tolfenamic Acid may increase the neuroexcitatory activities of Ciprofloxacin.
Tolmetin
Tolmetin may increase the neuroexcitatory activities of Ciprofloxacin.
Tolterodine
Tolterodine may increase the QTc-prolonging activities of Ciprofloxacin.
Tolvaptan
The serum concentration of Tolvaptan can be increased when it is combined with Ciprofloxacin.
Topotecan
The serum concentration of Topotecan can be increased when it is combined with Ciprofloxacin.
Toremifene
Ciprofloxacin may increase the QTc-prolonging activities of Toremifene.
Trandolapril
The risk or severity of ventricular arrhythmias can be increased when Trandolapril is combined with Ciprofloxacin.
Tranilast
Tranilast may increase the neuroexcitatory activities of Ciprofloxacin.
Trastuzumab
Trastuzumab may increase the cardiotoxic activities of Ciprofloxacin.
Trazodone
Trazodone may increase the QTc-prolonging activities of Ciprofloxacin.
Treprostinil
Treprostinil may increase the QTc-prolonging activities of Ciprofloxacin.
Triamcinolone
The risk or severity of adverse effects can be increased when Triamcinolone is combined with Ciprofloxacin.
Tribenoside
Tribenoside may increase the neuroexcitatory activities of Ciprofloxacin.
Tricalcium Phosphate
Calcium Phosphate can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Trimethoprim
Trimethoprim may increase the QTc-prolonging activities of Ciprofloxacin.
Trimipramine
Trimipramine may increase the QTc-prolonging activities of Ciprofloxacin.
Triptorelin
Triptorelin may increase the QTc-prolonging activities of Ciprofloxacin.
Tromethamine
Tromethamine can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Valdecoxib
Valdecoxib may increase the neuroexcitatory activities of Ciprofloxacin.
Valsartan
Valsartan may increase the arrhythmogenic activities of Ciprofloxacin.
Vandetanib
Ciprofloxacin may increase the QTc-prolonging activities of Vandetanib.
Vardenafil
Vardenafil may increase the QTc-prolonging activities of Ciprofloxacin.
Varenicline
The serum concentration of Varenicline can be increased when it is combined with Ciprofloxacin.
Vemurafenib
The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Ciprofloxacin.
Venlafaxine
Venlafaxine may increase the QTc-prolonging activities of Ciprofloxacin.
Vilanterol
Vilanterol may increase the QTc-prolonging activities of Ciprofloxacin.
Vincristine
The excretion of Vincristine can be decreased when combined with Ciprofloxacin.
Voriconazole
Voriconazole may increase the QTc-prolonging activities of Ciprofloxacin.
Vorinostat
Vorinostat may increase the QTc-prolonging activities of Ciprofloxacin.
Warfarin
Ciprofloxacin may increase the anticoagulant activities of Warfarin.
Xanthinol
The serum concentration of Xanthinol can be increased when it is combined with Ciprofloxacin.
Zileuton
Zileuton may increase the neuroexcitatory activities of Ciprofloxacin.
Ziprasidone
Ciprofloxacin may increase the QTc-prolonging activities of Ziprasidone.
Zofenopril
The risk or severity of ventricular arrhythmias can be increased when Zofenopril is combined with Ciprofloxacin.
Zomepirac
Zomepirac may increase the neuroexcitatory activities of Ciprofloxacin.
Zuclopenthixol
Ciprofloxacin may increase the QTc-prolonging activities of Zuclopenthixol.
